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Abstract
The present study was aimed to investigate the relationships between permeability and membrane retention values (logPe and 
MR) of the in vitro non-cellular permeability assay, corneal-PAMPA in comparison with experimental Caco-2 permeability data and 
calculated physicochemical properties (MW, clogP, clogD7.4 , TPSA). For the investigation, 50 structurally and physicochemically diverse 
drugs were selected and measured in PAMPA model optimized for corneal permeability. The results showed corneal-PAMPA model's 
orthogonality in terms of passive diffusion to the FDA approved Caco-2 as a gastrointestinal absorption model, while the comparison 
with physicochemical properties revealed trends between logPe , MR and the lipophilicity descriptors and TPSA.
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1 Introduction
The effective treatment of diseases affecting the human 
eye is of utmost importance as they might cause par-
tial visual impairment or even complete blindness [1]. 
For the treatment of the anterior segment of the eye, top-
ical drug administration is the preferred way of therapy. 
To this avail, eye drops, ophthalmic solutions, eye oint-
ments and gels, microemulsions, drug-eluting contact 
lenses, ocular inserts, liposomes, nano- and microparti-
cles etc. can be used [2–4]. However, ocular bioavailabil-
ity of these topically administered drugs is limited by sev-
eral factors: lacrimal fluid rapidly elutes a large portion 
of the applied drugs within a few minutes upon adminis-
tration [5]; the drug fraction absorbed through non-cor-
neal routes is mostly transferred into the systematic cir-
culation [6]. These result in a decreased bioavailability 
(usually < 5–10 %) [7, 8], while the therapeutic effect can 
mainly be attributed to the drug fraction absorbed via the 
corneal route [6]. The human cornea is a unique and com-
plex biological barrier which consists of five distinct layers: 
the epithelium, Bowman's layer, the stroma, Descemet's 
membrane, and the endothelium [6, 9, 10]. For the absorp-
tion of the drug into the aqueous humor it has to penetrate 
through these layers of hydrophilic and lipophilic charac-
ter, however, it has been reported that in the case of most 
drugs the epithelial layer is the rate-limiting barrier [11, 12] 
which is responsible for about 99 % of the resistance to the 
diffusion of APIs through the cornea [13].
To predict the corneal permeability of APIs, several 
methods exist: ex vivo models using the eyes or excised 
cornea of vertebrate animals (most often rabbit, pig or 
bovine eyes) [10], while to minimize the number of lab-
oratory animals sacrificed and to limit the cost of ex vivo 
studies, in  vitro cellular models using primary cell cul-
tures, immortalized cell lines, or reconstructed tissue 
cultures of rabbit or human origin [10, 14] are used and 
recently an in vitro non-cellular method, corneal-PAMPA 
has also been developed by our group to this avail [15].
The corneal-PAMPA method has been developed 
based on ex vivo rabbit corneal permeability data [7, 12] 
using the parallel artificial membrane permeability assay 
(PAMPA) [16]. Based on previous experience with the 
PAMPA model [17, 18], we investigated the effects of 
the composition of the artificial lipid membrane, the DMSO 
cosolvent content of the donor phase as well as different 
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buffer solutions in the model. We found that the best cor-
relation (R2 = 0.880) with the ex vivo data could be achieved 
using the following optimized conditions: iso-pH conditions 
using phosphate buffer saline (PBS, pH 7.4) without cosol-
vent, phosphatidylcholine (PC = 10.7 % (w/v); without cho-
lesterol) dissolved in a solvent mixture of hexane:dodeca-
ne:chloroform = 70:25:5 (v/v) as an artificial membrane and 
a 4 hour long incubation of the PAMPA plates at 35 °C.
In this study, we have investigated the orthogonality 
between corneal-PAMPA and the FDA approved industrial 
cellular permeability standard, Caco-2 based on experi-
mental data. We also aimed to investigate the extent of 
correlation between the experimentally determined cor-
neal-PAMPA data (permeability ( logPe ) and membrane 
retention (MR)) and basic physicochemical proper-
ties (MW and in silico predicted clogP, clogD7.4 , TPSA) 
to determine if it is possible to predict corneal permeabil-
ity values based on these basic descriptors.
2 Experimental
2.1 Materials
Analytical grade solvents such as acetonitrile (MeCN), 
chloroform, dodecane, hexane and formic acid were 
purchased from Merck KGaA (Darmstadt, Germany). 
Phosphate buffered saline (PBS) powder, L-α-
phosphatidylcholine (PC) and the reference materials 
(aldosterone, amitriptyline hydrochloride, antipyrine, 
atenolol, atropine sulfate, bupropion hydrochloride, car-
bamazepine, chloramphenicol, chlorpromazine hydro-
chloride, cimetidine hydrochloride, ciprofloxacin, clon-
idine, desipramine hydrochloride, diazepam, diclofenac 
sodium, diflunisal, diltiazem hydrochloride, ephedrine 
hydrochloride, etoposide, famotidine, furosemide, hal-
operidol, hydrocortisone, ibuprofen, imipramine hydro-
chloride, irbesartan, ketoprofen, labetalol hydrochloride, 
lidocaine, loperamide hydrochloride, meloxicam sodium, 
metoprolol, nadolol, naproxen, ofloxacin, phenytoin, pin-
dolol, pirenzepine 2 hydrochloride, piroxicam, prazosin 
hydrochloride, prednisolone, propranolol hydrochloride, 
quinine, sparfloxacin, theophylline, trimethoprim, ver-
apamil hydrochloride, warfarin) were purchased from 
Sigma Aldrich Co. Ltd. (Budapest, Hungary). Further ref-
erence materials (betaxolol hydrochloride, flurbiprofen) 
were purchased from Toronto Research Chemicals Inc. 
(North York, Toronto, Canada). In all experiments, dis-
tilled water was purified by the Millipore Milli-Q® 140 
Gradient Water Purification System.
2.2 Corneal-PAMPA measurements
For in vitro transcorneal permeability measurement the pre-
viously reported cornea-PAMPA method was used [15]. 
Briefly the drugs were dissolved in PBS buffer (pH 7.4) 
to make solutions of 100 μM nominal concentration. 
Before each assay the PBS solutions were homogenized 
by using an Eppendorf MixMate vortex mixer for 10–12 s 
and by an ultrasonic bath (Bandelin Sonorex Digiplus) 
for 10 min. For creation of the lipid membrane phosphati-
dylcholine (PC, 16 mg) was dissolved in a solvent mixture 
(70 % (v/v) hexane, 25 % (v/v) dodecane, 5 % (v/v) chloro-
form) and then each well of donor plate (MultiscreenTM-IP, 
MAIPN4510, pore size 0.45 mm; Millipore) was coated 
with the lipid solution (5 μL each). Then the hexane and 
chloroform were evaporated to form a PC lipid membrane 
with the concentration of 10.67 w/v% in each well. Then the 
donor plate was fit into the acceptor plate (Multiscreen 
Acceptor Plate, MSSACCEPTOR; Millipore) containing 
300 μL of PBS solution (pH 7.4), and 150–150 μL of the PBS 
solutions were put on the membrane of the donor plate. 
The donor plate was covered with a sheet of wet tissue paper 
and a plate lid to avoid evaporation. The plates were incu-
bated for 4 h at 35 °C (Heidolph Titramax 1000) followed 
by separation of PAMPA sandwich plates and determina-
tion of concentrations of the APIs in the donor and acceptor 
solutions by HPLC-DAD. The concentration of donor solu-
tions at time point zero was also determined using the same 
HPLC system. Test solutions from PAMPA experiments 
were prepared in 96-well plates and sealed before injection. 
For each assay 3 replicates per compounds were measured.
The effective permeability and membrane retention of 
drugs were calculated using Eq. (1) [16]:
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where Pe is the effective permeability coefficient (cm/s), 
A is the filter area ( 0.3 cm2 ), t is the incubation time (s), 
τss is the time to reach steady-state (s), rv is the volume 
ratio of aqueous compartments ( VD / VA ), VD and VA are 
the volumes in the donor ( 0.15 cm3 ) and acceptor phase 
( 0.3 cm3 ), cD (t) is the concentration of the compound in the 
donor phase at time point t ( mol/cm3 ), cD (0) is the concen-
tration of the compound in the donor phase at time point 
zero ( mol/cm3 ) and MR is the membrane retention factor, 
defined as [16]:
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where cA (t) is the concentration of the compound in the 
acceptor phase at time point t ( mol/cm3 ).
2.3 HPLC-methods
Quantitative chromatographic analyses were performed 
using an Agilent 1260 liquid chromatography system 
equipped with a vacuum degasser, a quaternary pump, 
a thermostatted autosampler, a column temperature con-
troller and a diode array detector (Agilent Technologies, 
Palo Alto, CA, USA) at 45 °C on a Kinetex® 2.6 µm C18 
100 Å LC column (30 × 3 mm) with a mobile phase flow 
rate of 1.1 mL / min. Composition of mobile phase A was 
0.1 % (v/v) formic acid in water, B was MeCN/water 
95/5 (v/v) with 0.1 % (v/v) of formic acid. A 3.91 min long, 
linear gradient program was applied: 0 % B in the first 
0.3 min, 0–100 % B between 0.3 and 1.8 min, then 100 % 
B was kept for another 0.6 min, and finally at 2.41 min 
the percentage of B was dropped to 0 %. This was fol-
lowed by an equilibration period of 1.5 min prior to the 
next injection. Chromatograms were recorded at the 
wavelength of 200–500 nm, integration was carried out 
at the UVmax of each compound. The applied injection vol-
ume was 6 μL. ChemStation B.04.03 was used for data 
acquisition and analysis.
3 Results and discussion
For our experiments, we have selected fifty APIs of com-
mercially available drugs (Table 1) with diverse molecular 
structure and physicochemical parameters covering a broad 
range of molecular weight (MW = 165 – 589), lipophilicity 
descriptors (clogP = –2.0 – 5.4, clogD7.4 = –2.7 – 4.2) and 
topological polar surface area (TPSA = 3 – 176 Å2). Table 1 
also contains the in vitro corneal permeability and mem-
brane retention values measured by the corneal-PAMPA 
method [15], as well as previously reported experimental 
Caco-2 permeability data [19–21].
As we can see in Fig. 1 only a weak correlation could 
be observed between the in vitro experimental corne-
al-PAMPA and Caco-2 permeability values (Pearson cor-
relation coefficient, r = 0.354), which indicates that our 
model is independent of this generally accepted gastro-
intestinal permeability model and supports its adequacy 
for cornea-specific in vitro measurements.
To investigate the correlation of corneal permeabil-
ity values and basic physicochemical parameters clogP, 
clogD7.4 and TPSA values have been predicted using 
the Marvin calculator plugin [22] (Table 1). Determination 
of correlation coefficients and model fitting was carried 
out using GraphPad Prism v.7.03. [23].
Table 1 In silico predicted physicochemical parameters and experimental corneal-PAMPA and Caco-2 permeability values of investigated APIs
API name MW clogP* clogD7.4*
TPSA* 
( Å2 )
Corneal-PAMPA Caco-2
Pe 
(10−6 cm/s) SD logPe SD MR SD
Pe 
(10-6 cm/s) logPe Ref.
aldosterone 360.45 1.06 1.06 91.67 9.05 0.12 −5.04 0.01 4.06 1.65 48.98 −4.31 [19]
amitriptyline 277.41 4.81 2.48 3.24 24.52 2.43 −4.61 0.04 73.36 1.04 20.89 −4.68 [19]
antipyrine 188.23 1.22 1.22 23.55 15.46 2.15 −4.81 0.06 1.50 0.40 28.18 −4.55 [20]
atenolol 266.34 0.43 −1.80 84.58 0.00 - - - 2.58 0.44 0.36 −6.44 [20]
atropine 289.38 1.57 −0.41 49.77 6.81 1.97 −5.18 0.13 3.93 0.36 19.50 −4.71 [19]
betaxolol 307.43 2.54 0.31 50.72 23.67 2.82 −4.63 0.05 10.31 2.17 30.20 −4.52 [20]
bupropion 239.74 3.27 2.39 29.10 32.65 0.30 −4.47 0.05 34.44 2.38 151.36 −3.82 [21]
carbamazepine 236.27 2.77 2.77 46.33 29.68 3.15 −4.53 0.05 8.26 1.91 5.01 −5.30 [21]
chloramphenicol 323.13 0.88 0.86 112.70 2.53 0.08 −5.60 0.01 8.40 0.61 20.42 −4.69 [20]
chlorpromazine 318.86 4.54 2.74 6.48 6.73 2.31 −5.19 0.15 86.24 0.98 19.95 −4.70 [20]
cimetidine 252.34 −0.11 −0.22 88.89 0.00 - - - 1.50 1.29 1.29 −5.89 [20]
ciprofloxacin 331.35 −0.86 −0.87 72.88 0.25 0.19 −6.70 0.28 4.21 1.36 2.95 −5.53 [21]
clonidine 230.09 2.49 1.66 36.42 24.05 2.40 −4.62 0.04 6.91 4.97 25.70 −4.59 [20]
desipramine 266.39 3.90 1.37 15.27 54.42 1.33 −4.26 0.01 27.46 3.05 21.38 −4.67 [20]
diazepam 284.74 3.08 3.08 32.67 60.28 2.70 −4.22 0.02 38.90 3.86 47.86 −4.32 [20]
diclofenac 296.15 4.26 1.10 49.33 19.96 2.63 −4.70 0.06 8.33 1.81 53.70 −4.27 [21]
diflunisal 250.2 3.91 0.41 57.53 5.84 0.36 −5.23 0.03 14.29 0.79 12.59 −4.90 [19]
diltiazem 414.52 2.73 1.89 59.08 44.73 0.40 −4.35 0.00 28.49 4.44 41.69 −4.38 [20]
ephedrine 165.24 1.32 −0.78 32.26 12.18 1.26 −4.92 0.05 8.85 0.51 10.23 −4.99 [19]
etoposide 588.56 1.16 1.16 160.83 0.73 0.09 −6.14 0.05 8.38 1.74 1.00 −6.00 [21]
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Fig. 2 shows the relationship between the in sil-
ico parameters and permeability and membrane reten-
tion values of corneal-PAMPA. In the case of logPe val-
ues, only a weak correlation could be observed with MW 
(Fig. 2 (A)), while the comparison revealed a moderate cor-
relation with clogD7.4 (Fig. 2 (E)), a strong positive correla-
tion in the case of clogP (Fig. 2 (C)) and a strong negative 
correlation with TPSA (Fig. 2 (G)). These are in agreement 
with the fact that the more lipophilic a drug is, the eas-
ier it can partition into the membrane (PC, in our model). 
On the other hand, a large polar surface area will hinder 
that process, therefore a negative trend can be expected. 
However, the goodness of fit ( R2 ) values of the straight 
Fig. 1 Correlation between experimental corneal-PAMPA and Caco-2 
permeability values, r is the Pearson correlation coefficient [23].
API name MW clogP* clogD7.4*
TPSA* 
( Å2 )
Corneal-PAMPA Caco-2
Pe 
(10−6 cm/s) SD logPe SD MR SD
Pe 
(10-6 cm/s) logPe Ref.
famotidine 337.44 −1.95 −2.67 175.83 0.38 0.31 −6.55 0.42 1.11 0.68 0.89 −6.05 [19]
flurbiprofen 244.27 3.94 1.07 37.30 16.47 1.77 −4.79 0.05 1.94 2.34 33.88 −4.47 [21]
furosemide 330.74 1.75 −1.25 122.63 1.07 0.80 −6.10 0.45 0.56 2.07 0.31 −6.51 [20]
haloperidol 375.87 3.66 2.93 40.54 40.66 6.60 −4.40 0.07 41.16 9.67 15.85 −4.80 [21]
hydrocortisone 362.47 1.28 1.28 94.83 5.58 1.96 −5.28 0.17 10.80 3.08 21.88 −4.66 [20]
ibuprofen 206.29 3.84 1.34 37.30 21.90 2.75 −4.66 0.06 1.26 2.20 52.48 −4.28 [20]
imipramine 280.42 4.28 2.48 6.48 15.59 0.30 −4.61 0.26 50.34 4.51 14.13 −4.85 [20]
irbesartan 428.54 5.39 4.23 87.13 2.23 0.51 −5.66 0.10 8.55 1.36 11.75 −4.93 [19]
ketoprofen 254.29 3.61 0.39 54.37 8.36 0.57 −5.08 0.03 0.00 1.06 46.77 −4.33 [21]
labetalol 328.41 1.89 1.26 95.58 3.78 0.72 −5.43 0.09 18.73 2.55 9.33 −5.03 [20]
lidocaine 234.34 2.84 2.33 32.34 61.68 1.07 −4.21 0.01 7.07 1.25 61.66 −4.21 [20]
loperamide 477.05 4.77 2.77 43.78 37.76 3.77 −4.42 0.04 37.23 1.59 20.89 −4.68 [19]
meloxicam 351.4 1.60 −1.10 99.60 6.99 0.57 −5.16 0.03 4.22 2.24 19.50 −4.71 [20]
metoprolol 267.37 1.76 −0.47 50.72 14.19 1.22 −4.85 0.04 2.95 1.75 25.70 −4.59 [20]
nadolol 309.41 0.87 −1.44 81.95 0.00 - - - 4.12 0.87 3.89 −5.41 [20]
naproxen 230.26 2.99 −0.05 46.53 11.51 1.04 −4.94 0.04 0.00 0.31 14.79 −4.83 [20]
ofloxacin 361.37 0.09 −0.51 73.32 1.56 0.54 −5.83 0.14 3.77 1.13 21.38 −4.67 [19]
phenytoin 252.27 2.15 2.11 58.20 19.05 1.21 −4.72 0.03 20.14 2.25 26.92 −4.57 [20]
pindolol 248.33 1.69 −0.53 57.28 9.05 1.51 −5.05 0.08 2.90 1.64 16.60 −4.78 [20]
pirenzepine 351.41 0.97 0.76 68.78 0.34 0.27 −6.55 0.33 9.62 1.72 0.44 −6.36 [20]
piroxicam 331.35 0.60 −1.52 99.60 14.11 1.70 −4.85 0.05 3.95 1.57 35.48 −4.45 [20]
prazosin 383.41 1.65 1.43 106.95 7.85 3.20 −5.13 0.18 40.35 6.19 43.65 −4.36 [20]
prednisolone 360.45 1.27 1.27 94.83 3.50 0.66 −5.46 0.08 11.57 2.46 20.42 −4.69 [19]
propranolol 259.35 2.58 0.36 41.49 37.05 2.57 −4.43 0.03 21.50 1.36 26.30 −4.58 [20]
quinine 324.42 2.51 0.86 45.59 20.61 0.26 −4.69 0.01 20.42 1.67 112.20 −3.95 [19]
sparfloxacin 392.41 −0.08 −0.08 98.90 4.86 1.57 −5.33 0.16 6.95 1.70 32.36 −4.49 [19]
theophylline 180.17 −0.77 −0.89 69.30 4.36 1.31 −5.38 0.15 1.78 0.34 44.67 −4.35 [20]
trimethoprim 290.32 1.28 1.10 105.51 6.14 1.78 −5.22 0.12 6.83 2.05 87.10 −4.06 [21]
verapamil 454.61 5.04 2.79 63.95 29.00 4.19 −4.80 0.15 11.56 21.08 26.30 −4.58 [20]
warfarin 308.33 2.74 0.94 63.60 12.66 1.83 −4.73 0.23 23.19 25.42 13.80 −4.86 [20]
* clogP, clogD7.4 and TPSA values were predicted by the Chemaxon/Marvin Calculator plugin [22].
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Fig. 2 Correlation between experimental corneal permeability ( logPe ), membrane retention (MR) and in silico predicted physicochemical parameters 
(clogP: the logarithm of the partition coefficient, clogD7.4 : the logarithm of the distribution coefficient at pH 7.4, TPSA: topological polar surface 
area). Physicochemical parameters were predicted by the Chemaxon/Marvin Sketch 19.19.0 plugin [22]. r is the Pearson correlation coefficient, 
R2 is the goodness of fit of the fitted model calculated using GraphPad Prism v. 7.03 [23].
lines fitted onto the datapoint using linear regression anal-
ysis were low, only poor fits could be achieved in all cases.
Similar observations could be made in the case of 
MR values: it showed a very weak correlation with MW 
(Fig. 2 (B)), moderately strong correlation with the lipo-
philicity descriptors (clogD7.4 and clogP (Figs. 2 (D) and (F)) 
and TPSA (Fig. 2 (H)). The relationship between MR and 
the lipophilicity descriptors seemed to be non-linear, instead 
a sigmoidal model could be fitted over the datapoints, 
although it showed only a poor fit. In the case of TPSA and 
MR a fair fit could be observed using an exponential model.
The observed relationships between logPe , MR and 
the predicted physicochemical descriptors show that using 
only one basic parameter separately would not result 
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